Errol Moras MD retweeted
I created LearnCoronary (learncoronary.com), an interactive tool designed to help general cardiology fellows and other early-career learners better understand coronary angiography and the spatial relationships between different angiographic views.
#cardiotwitter @OpenAI
Errol Moras MD retweeted
I built an interactive echocardiography tutorial with Claude Code.
Chapter 07: a 3D heart, the standard imaging views, the probe position, and simulated ultrasound video.
Wonderful memories from #ACC26 weeknd in NOLA
Had the opportunity to present a moderated abstract, but the best highlight was reconnecting with so many colleagues !!
Grateful to @ACCinTouch for the opportunity to contribute as a #SoMe Ambassador
@UTHeartVascular @ACCinTouch
Errol Moras MD retweeted
Summary of all Late-Breaking Trials at #ACC2026 – take home points
@ACCinTouch @ACCmediacenter @JACCJournals
1. HI-PEITHO: Ultrasound-facilitated catheter-directed thrombolysis led to a lower risk of PE-related death, cardiopulmonary decompensation or collapse, or recurrence of PE. vs anticoagulation alone in intermediate-high risk PE.
Errol Moras MD retweeted
Presented at #ACC26:
Among patients with a preserved ejection fraction at least 1 year after myocardial infarction, stopping beta-blockers was noninferior to continuing therapy with respect to major clinical outcomes. Full SMART-DECISION trial results: nejm.org/doi/full/10.1056/NE…
@ACCinTouch
ALT American College of Cardiology Annual Meeting Original Article | MAR 30, 2026 | NEJM.org Discontinuation of Beta-Blocker Therapy after Myocardial Infarction (SMART-DECISION) Figure 2. Death from Any Cause, Recurrent Myocardial Infarction, or Hospitalization for Heart Failure.
Errol Moras MD retweeted
GoFreshRx trial: Could improving access to healthy, DASH-patterned groceries lower blood pressure among Black residents of Boston with treated hypertension? #ACC26 View slides here: clinicaltrialresults.org/wp-…
Errol Moras MD retweeted
CHIP-BCIS3 trial: Percutaneous LV unloading with microaxial flow pump did not reduce major adverse clinical outcomes vs. standard of care in patients with severe LV dysfunction undergoing complex PCI. #ACC26 View the slides here: clinicaltrialresults.org/wp-…
Errol Moras MD retweeted
IMPEDANCE-HFpEF trial: Therapy guided by lung impedance monitoring reduced HF hospitalizations and mortality in HFpEF patients through earlier detection and correction of pulmonary congestion. #ACC26 View slides here: clinicaltrialresults.org/wp-…
Errol Moras MD retweeted
HOST-EXAM trial 10-year results: Clopidogrel monotherapy is superior to aspirin for chronic maintenance after PCI, significantly reducing both thrombotic and bleeding events. #ACC26 View slides here: clinicaltrialresults.org/wp-…
Errol Moras MD retweeted
PRO-TAVI trial: Deferring PCI was non-inferior to routine PCI before TAVI for the 1-year composite of all-cause mortality, MI, stroke, and major bleeding, suggesting its appropriate role in selected CAD patients. #ACC26 View slides here: clinicaltrialresults.org/wp-…
Errol Moras MD retweeted
CHAMPION-AF trial: Left atrial appendage closure with the WATCHMAN FLX device had comparable 3-year risk of CV death/stroke/systemic embolism but reduced clinically-relevant non-procedural bleeding vs. DOACs in AFib. #ACC26 View Slides Here: clinicaltrialresults.org/wp-…
Excited to kick off #ACC26 tomorrow🫀
Honored to serve as a Social Media Ambassador
So many exciting sessions ahead.
I’ll be sharing key highlights, late-breaking trials, and clinical takeaways throughout.
Follow along if you’re not in NOLA📍
@ACCinTouch @JACCJournals
Errol Moras MD retweeted
Interact 🔍 with the🆕 2026 ACC/AHA Guideline on the Management of Dyslipidemia 🫀 at ASCVD.org ⚙️
📽️youtube.com/watch?v=1tYHCQYb…
@YaleCardiology @SmidtHeart @JACCJournals
ICYMI: ACC/AHA & 9 other leading medical associations released an updated clinical guideline for managing #dyslipidemia. About 1 in 4 US adults has high LDL-C, raising risk of heart attack & stroke. jacc.org/doi/10.1016/j.jacc.…
#JACC #ClinicalGuidelines #cvLipids #ASCVD
Errol Moras MD retweeted
📣 #ACCFITs: Connect w/ leaders, gain insights into career pathways & emerging trends, & build your professional network in cardiology at #ACC26 #ACCFIT Mix 'N' Mingle! 👇
More details in the program planner ➡️ bit.ly/4bnz7zU
@drapurvapopat @SaadUrRahman55 @Zill_cardio
Errol Moras MD retweeted
#Shock care is evolving—be there when it happens. ⚡
@HoustonShockHSS | March | #Houston
Learn from the experts. #HSS26
Errol Moras MD retweeted
Excitement is building for #ACC26! 🚀
Meet our Social Media Ambassadors as they gear up to share cutting‑edge science, key insights, and can’t‑miss updates.
📲 Follow along and stay tuned for what’s ahead! 👉 bit.ly/4jKa7Xh
Errol Moras MD retweeted
Warm congratulations to our new Cardiology Fellows! 🎉
Wishing them a great start to this next chapter and looking forward to a wonderful year together. @UTHeartVascular
Thrilled and excited to share that I have matched at @UTHealthHouston for my Cardiovascular Disease Fellowship
Incredibly grateful for my mentors, family, and friends whose support made this possible.Excited for this new chapter !!!
Errol Moras MD retweeted
A clinic visit is never routine for our patients. It can be the event of their week or even their month. Writing about the day I finally understood that.
Read the new Editor’s Page in JACC:
“The Day I Became a Doctor”
jacc.org/doi/10.1016/j.jacc.…
@JACCJournals @YaleMed
